Search Results - "Krekow, L"

0151 Adjuvant dose-dense adriamycin plus cytoxan followed by dose-dense nab -paclitaxel is safe in women with early-stage breast cancer: A pilot study by Pippen, J, O'Shaughnessy, J, Ambro, S, Krekow, L, Stokoe, C, Bhar, P, Iglesias, J, Robert, N

Get full text

Safety data from a phase II trial of weekly nab-paclltaxel In combination with bevacizumab as first-line treatment In metastatlc breast cancer by Danso, M, Blum, J, Robert, N, Krekow, L, Rotche, R, Smith, D, Richards, P, Anderson, T, Richards, D, O'Shaughnessy, J

Get full text

Temperature Dependence and Independence of Effects of Pentobarbital on Visual Evoked Potentials of Rats by Hetzler, Bruce E, Krekow, Lea K

“…Visual cortex flash evoked potentials (FEPs), pattern reversal evoked potentials (PREPs), and body temperature were measured in hooded rats following IP…”
Get full text

Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062 by O'Shaughnessy, J, Koeppen, H, Crockett, M, Lackner, M, Spoerke, JM, Wilson, T, Levin, MK, Pippen, J, Paul, D, Stokoe, C, Blum, J, Holmes, FA, Lindquist, DL, Krekow, L, Vukelja, SJ, Sedlacek, S, Rivera, R, Brooks, RJ, McIntyre, KJ, Schwartz, JE, Jones, S

“…Abstract Background: USON 01062 (O’Shaughnessy J, et al. Proc SABCS, 2010, abst S4-2) showed no improvement in the primary endpoint of disease-free survival…”
Get full text

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim by Jones, S, Paul, D, Sedlacek, S, Vukelja, S, Wilks, ST, Stokoe, C, Osborne, CR, Krekow, L, McIntyre, K, Holmes, FA, Guerra, L, Zhan, F, Asmar, L, O'Shaughnessy, J, Blum, JL

“…Abstract Background In our original doxorubicin-cyclophosphamide/docetaxel-cyclophosphamide (AC/TC) adjuvant study (JCO 27: 1177–1183, 2009), we reported an…”
Get full text

Abstract P2-05-06: Quantitative measurement of HER2 expression in breast cancers: comparison with “real world” HER2 testing in a multi-center Collaborative Biomarker Study (CBS) and correlation with clinicopathological features by Yardley, DA, Kaufman, PA, Adams, JW, Krekow, L, Savin, M, Lawler, WE, Zrada, S, Starr, A, Einhorn, H, Schwartzberg, LS, Huang, W, Weidler, J, Lie, Y, Paquet, A, Haddad, M, Anderson, S, Brigino, M, Bosserman, L

“…Abstract Background: Accurate determination of HER2 status is critical in determining appropriate therapy for breast cancer patients. The HERmark® assay is a…”
Get full text

Incidence of and Predictive Factors for Recovery of Ovarian Function on Letrozole in ER-Positive Breast Cancer Patients in Their Forties Who Cease Menstruating with Adjuvant Chemotherapy by Krekow, L., Krekow, L., Collea, R., Collea, R., Papish, S., Papish, S., Negron, A., Negron, A., Resta, R., Resta, R., Vukelja, S., Vukelja, S., Donato, J., Guerra, L., Asmar, L., O'Shaughnessy, J., O'Shaughnessy, J.

“…Abstract Background: We conducted an open-label pilot study of 2 years of aromatase inhibitor (AI) therapy in women in their 40's with ER-positive breast…”
Get full text

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses by Pippen, J. E., Paul, D., Stokoe, C. T., Blum, J. L., Krekow, L., Holmes, F. A., Lindquist, D. L., Sedlacek, S. M., Rivera, R. R., Brooks, R. J., Vukelja, S. J., McIntyre, K., Lopez-Diaz, C., O'Shaughnessy, J.

“…Abstract only…”
Get full text

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer by O'Shaughnessy, J, Paul, D, Stokoe, C, Pippen Jr, J, Blum, JL, Krekow, L, Holmes, FA, Vukelja, S, Lindquist, D, Sedlacek, S, Rivera, R, Brooks, R, McIntyre, K, Pluenneke, R, Schwartz, J, Jones, S, Brownstein, C, Gilberg, F.

“…Abstract Background: Combination regimens incorporating anthracyclines and taxanes are among the most effective for EBC and are particularly suitable for pts…”
Get full text

Phase II trial of weekly nab- paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer by Danso, M. A., Blum, J. L., Robert, N. J., Krekow, L., Rotche, R., Smith, D. A., Richards, P., Anderson, T., Richards, D. A., O'Shaughnessy, J.

“…Abstract only…”
Get full text

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor by Wright, GL, Blum, J, Krekow, LK, McIntyre, KJ, Wilks, ST, Rabe, AC, Vukelja, SJ, Andersen, JC, Wang, Y, Asmar, L, O'Shaughnessy, J

“…Abstract Introduction: Fulvestrant is an effective endocrine therapy in patients with ER+ metastatic breast cancer (MBC) that has become resistant to…”
Get full text

P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer by Holmes, FA, Espina, V, Liotta, LA, Chang, JC, Nagarwala, YX, Danso, M, McIntyre, K, Osborne, CR, Krekow, LK, Gagnon, RC, Mahoney, JM, O'Shaughnessy, JA

“…Abstract Background 15% of curative HER2−positive patients (pts) treated with standard trastuzumab (T)-based chemotherapy regimens recur. Our prior report…”
Get full text